101 related articles for article (PubMed ID: 12760291)
1. MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma.
Ho DM; Hsu CY; Ting LT; Chiang H
Am J Clin Pathol; 2003 May; 119(5):715-22. PubMed ID: 12760291
[TBL] [Abstract][Full Text] [Related]
2. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Holden JA; Townsend JJ
Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
[TBL] [Abstract][Full Text] [Related]
5. No prognostic impact of survivin expression in glioblastoma.
Preusser M; Gelpi E; Matej R; Marosi C; Dieckmann K; Rössler K; Budka H; Hainfellner JA
Acta Neuropathol; 2005 May; 109(5):534-8. PubMed ID: 15843906
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
Chiba Y; Hashimoto N; Tsuboi A; Rabo C; Oka Y; Kinoshita M; Kagawa N; Oji Y; Sugiyama H; Yoshimine T
Brain Tumor Pathol; 2010 Apr; 27(1):29-34. PubMed ID: 20425045
[TBL] [Abstract][Full Text] [Related]
8. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
9. Lack of prognostic value of topoisomerase II alpha in patients with breast cancer: analysis with tissue microarray.
Sheen-Chen SM; Huang CY; Zhang H; Huang CC; Tang RP
Anticancer Res; 2010 Jun; 30(6):2459-62. PubMed ID: 20651408
[TBL] [Abstract][Full Text] [Related]
10. Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents.
Bowers DC; Gargan L; Kapur P; Reisch JS; Mulne AF; Shapiro KN; Elterman RD; Winick NJ; Margraf LR
J Clin Oncol; 2003 Aug; 21(15):2968-73. PubMed ID: 12885817
[TBL] [Abstract][Full Text] [Related]
11. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
12. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods.
Hsu CY; Ho DM; Yang CF; Chiang H
Mod Pathol; 2003 Sep; 16(9):951-7. PubMed ID: 13679460
[TBL] [Abstract][Full Text] [Related]
13. Ki-S1--a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy.
Kuropkat C; Rudolph P; Parwaresch R; Werner JA
Anticancer Res; 2003; 23(5A):3965-70. PubMed ID: 14666704
[TBL] [Abstract][Full Text] [Related]
14. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining.
Ludvíková M; Holubec L; Ryska A; Topolcan O
Anticancer Res; 2005; 25(3A):1835-40. PubMed ID: 16033110
[TBL] [Abstract][Full Text] [Related]
15. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
16. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Segawa E; Sakurai K; Kishimoto H; Takaoka K; Noguchi K; Hashitani S; Hirota S; Urade M
Oral Oncol; 2008 Jul; 44(7):664-71. PubMed ID: 17996482
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer.
Gotlieb WH; Goldberg I; Weisz B; Davidson B; Novikov I; Kopolovic J; Ben-Baruch G
Gynecol Oncol; 2001 Jul; 82(1):99-104. PubMed ID: 11426969
[TBL] [Abstract][Full Text] [Related]
20. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis.
Manaios L; Tsiambas E; Alevizaki M; Karameris A; Alexopoulou D; Lambropoulou S; Moreas H; Kravvaritis C; Fotiades PP; Goula K; Patsouris E; Athanassiou AE; Koutras D; Katsilambros N
J BUON; 2008; 13(4):537-41. PubMed ID: 19145676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
